The aim of the present study was to evaluate the effect of pre-procedural single high loading
dose (40 mg) of rosuvastatin on the primary end-points of all cause mortality and composite
of death or myocardial infarction from cardiovascular (CV) causes, target vessel
revascularization (TVR), or stroke.